Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

SGLT 2 inhibitors in Type 1 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Natarbejde og komplikationer i graviditeten

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Discontinuation of antidepressants

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Donorsøgning til Hæmatopoietisk stamcelle transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Kan prævention udløse depression?

    Research output: Contribution to journalEditorialResearch

  5. Somatiske årsager til akut opståede psykiatriske tilstande hos børn og unge

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been approved for the treatment of Type 1 diabetes (T1D) with significant reductions in HbA1c, weight, total daily insulin dose and significant increase in time in range without an increased risk of hypoglycaemia. The use of SGLT2i in T1D has, however, shown a significant increase from 1,9% to 4,0% in the risk of diabetic ketoacidosis (DKA), which may present as euglycaemic DKA. In this review we therefore find it important to know, that DKA may present with normal/near-normal blood glucose levels, if the patient is treated with an SGLT2i.

Original languageEnglish
JournalUgeskrift for Laeger
Volume182
Issue number35
ISSN0041-5782
Publication statusPublished - 24 Aug 2020

ID: 61156589